Picture Kentro Design Corporate and Web Design for Start Ups 2x 650x80px

Document › Details

Marinomed Biotech AG. (11/5/18). "Press Release: Marinomed Announces Its Intention to Launch an Initial Public Offering and Listing on the Vienna Stock Exchange [Not for US, AU, CA, JP, et al.]". Vienna.

	Region	Wien (Vienna)
	Country	Austria
	Organisation	Marinomed Biotech AG (VSE: MARI)
	Organisation 2	Vienna Stock Exchange (VSE)
	Product	Marinosolv® technology platform
	Product 2	Carragelose®
	Index term	Marinomed–SEVERAL: investment, 201811–201901 IPO €19.5m+€2.925m with 260k+39k new bearer shares at €75/share
	Person	Grassauer, Andreas (Marinomed Biotechnologie GmbH 201307 CEO)
	Person 2	Schmidt, Pascal (Marinomed 201808– CFO before Raymond James Financial + Mummert & Co + Infineon Ventures)

Original document
accessed by [iito] on 2018-12-01

Record changed: 2018-12-02

More documents for Marinomed Biotech AG (VSE: MARI)

[1] Marinomed Biotech AG. (2/15/22). "Press Release: Marinomed Receives €6m with Final Tranche of Financing Agreement with EIB to Invest in Proprietary R&D Pipeline". Korneuburg....
[2] Marinomed Biotech AG. (1/21/22). "Press Release: Marinomed Announces the Appointment of Dr. Cornelia Kutzer as Chief Business Officer". Korneuburg....
[3] Marinomed Biotech AG. (1/29/19). "Press Release: Marinomed Sets Offer Price at 75 Euro per Share (Adhoc-News)"....
[4] Marinomed Biotech AG. (1/29/19). "Press Release: Marinomed Announces Strong Investor Demand and Expected Offer Price (Adhoc-News)"....
[5] Marinomed Biotech AG. (1/23/19). "Press Release: Marinomed Resumes Offer Period of the IPO (Adhoc-News)"....
[6] Marinomed Biotech AG. (1/21/19). "Press Release: Partnership in China and EIB Financing [Not for US, AU, CA, JP or any other jurisdiction where prohibited by applicable law]". Vienna....
[7] Marinomed Biotech AG. (11/29/18). "Press Release: Marinomed Suspends Offer Period of the Current IPO [Adhoc-News]"....
[8] Marinomed Biotech AG. (11/28/18). "Press Release: Viennese Biotech Company Marinomed Demonstrates the Benefits of Its Patented Marinosolv Technology"....
[9] Marinomed Biotech AG. (11/16/18). "Press Release: Marinomed Determines IPO Timeline and Terms [Adhoc-News]"....
[10] Marinomed Biotech AG. (10/19/18). "Press Release: Initiation of First Marinosolv Clinical Trial (Ph III)"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]